Alexandre Grassin
Corporate Officer/Principal at Calliditas Therapeutics Suisse SA
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Elias Papatheodorou | M | 55 |
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | 9 years |
Jason Hanson | M | 55 | 1 years | |
Gerry Brunk | M | 55 | 1 years | |
Claudio Nessi | M | 56 |
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | - |
Alexander Nichols | M | 38 | 1 years | |
Ryan Daws | M | 50 | 1 years | |
Linda Armstrong | M | 61 | 17 years | |
Philippe Wiesel | M | - |
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | 14 years |
Jasper Bos | M | 49 | 1 years | |
Jesús Martin-Garcia | M | 62 |
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | - |
Richard Bryce | M | 66 | 1 years | |
James Sullivan | M | 45 | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Joseph Jimenez | M | 64 | 11 years | |
Dirk van de Put | M | 63 | 1 years | |
Mun Tak Yang | F | 70 | - | |
Ann Marie Fudge | F | 72 | - | |
William Brody | M | 80 | - | |
Hans Jörg Reinhardt | M | 68 | 28 years | |
Pablo Cagnoni | M | 60 | 4 years | |
Dean Hakanson | M | 72 | 1 years | |
Theresa Matkovits | M | 56 | 13 years | |
Armand Sohet | M | 59 | 1 years | |
Jan Egbert de Vries | M | 80 | 13 years | |
Megan Wherry Menner | F | - | 4 years | |
Michael Singer | M | 51 | 3 years | |
Jeanette Wood | M | 72 |
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | 2 years |
Peter Elam | M | - | 8 years | |
Larry P. Allgaier | M | - | 6 years | |
Barbara Weber | M | 67 | 6 years | |
Udit Batra | M | 53 | 2 years | |
Judith Klimovsky | M | 67 | 8 years | |
Liu Hui | M | 51 | 6 years | |
Viviane Monges | F | 60 | 2 years | |
Jason Meyenburg | M | 47 |
Alexion Pharma GmbH
| 4 years |
Stefan Blarer | M | - | 10 years | |
Nadia Dac | F | 54 | 4 years | |
Rafael Torgovicky | M | - | 1 years | |
Roger Sawhney | M | 54 | 3 years | |
James Wassil | M | 54 | 7 years | |
Yuan Xu | M | 56 | 6 years | |
Kleem Chaudhary | M | 48 | 7 years | |
Brian Hubbard | M | - | 6 years | |
Yong Qing Luo | M | 54 | 2 years | |
Sabrina Comic Savic | F | - | 12 years | |
Christian Mandl | M | - | 6 years | |
Peter Maag | M | 57 | 3 years | |
Beth Calitri | F | - | 8 years | |
Andrew Knudten | M | - | 3 years | |
Guy Rousseau | M | - | 6 years | |
Sarah Boyce | F | 52 | 10 years | |
William George | M | 81 | 10 years | |
Raymund Breu | M | 79 | 14 years | |
Jonathan Symonds | M | 66 | 5 years | |
Urs Bärlocher | M | 82 | 11 years | |
Paul Choffat | M | - | 5 years | |
Thomas Ebeling | M | 65 | 7 years | |
Andreas Rummelt | M | 67 | 4 years | |
Chandra Vargeese | M | 63 | 6 years | |
Leon V. Schumacher | M | - | - | |
Stéphane Verdood | M | - |
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | - |
Ernest Loumaye | M | 71 |
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | 5 years |
Enrique Carrazana | M | 62 | 9 years | |
Gilles Nobécourt | M | 67 |
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | - |
Joseph McCracken | M | 70 |
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | - |
Charl van Zyl | M | 57 | 3 years | |
Ludwig Hantson | M | 61 | 9 years | |
Peder Sven Walberg | M | 50 | 2 years | |
Ben T. G. Tan | M | - | 3 years | |
Meenu Chhabra Karson | F | 51 | 1 years | |
Mason W. Freeman | M | 73 | 2 years | |
Thomas McCourt | M | 66 | 7 years | |
John Martin Manser | M | 77 | 11 years | |
Jeffrey George | M | 51 | - | |
Leone Patterson | F | 61 | 1 years | |
Seth Brodsky | M | - | 4 years |
Statistics
Country | Connections | % of total |
---|---|---|
Switzerland | 68 | 90.67% |
Canada | 7 | 9.33% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Alexandre Grassin
- Personal Network